ENA-001 for Opioid Induced Respiratory Depression

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

November 5, 2025

Study Completion Date

November 5, 2025

Conditions
Respiratory Depression
Interventions
DRUG

ENA-001

Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.

DRUG

Placebo Comparator

Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.

Trial Locations (1)

66212

RECRUITING

Dr. Vince Clinical Research, Overland Park

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Enalare Therapeutics Inc.

INDUSTRY